Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
verfasst von:
Chakrapani Balijepalli, Rohan Shirali, Prashanth Kandaswamy, Anastasia Ustyugova, Egon Pfarr, Søren S. Lund, Eric Druyts
In the original publication, Figure 3 was incorrectly published. The authors have updated figure 3 and the corrected Fig. 3 is given below.
Fig. 3
Plots presenting indirect comparisons of empagliflozin versus other glucose-lowering drugs
×
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
verfasst von
Chakrapani Balijepalli Rohan Shirali Prashanth Kandaswamy Anastasia Ustyugova Egon Pfarr Søren S. Lund Eric Druyts
